Sign In
Buy GOSS
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
09:00am, Wednesday, 18'th Mar 2026
Gossamer Bio CEO Expressed Optimism About PROSERA Trial Outcome; the Study Missed Its Primary Endpoint Months Later NEW YORK, March 18, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) sharehold
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
06:11pm, Tuesday, 17'th Mar 2026
Gossamer Bio (GOSS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.15 per share a year ago.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
06:10pm, Tuesday, 17'th Mar 2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors a
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
04:01pm, Tuesday, 17'th Mar 2026
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hyper
Investigation Alert: Gossamer Bio, Inc. (GOSS) Under Scrutiny - Contact Levi & Korsinsky for Details
12:12am, Monday, 16'th Mar 2026
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
10:00am, Thursday, 12'th Mar 2026
NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised t
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
04:59pm, Tuesday, 10'th Mar 2026
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are
Gossamer Bio (NASDAQ:GOSS) versus Actuate Therapeutics (NASDAQ:ACTU) Critical Survey
02:26am, Tuesday, 10'th Mar 2026
Actuate Therapeutics (NASDAQ: ACTU - Get Free Report) and Gossamer Bio (NASDAQ: GOSS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the t
Lost Investment in Gossamer Bio, Inc. (GOSS)? Levi & Korsinsky Launches Securities Fraud Investigation
12:08am, Monday, 09'th Mar 2026
New York, New York--(Newsfile Corp. - March 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerni
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $6.67 Average Target Price from Brokerages
04:03am, Saturday, 07'th Mar 2026
Gossamer Bio, Inc. (NASDAQ: GOSS - Get Free Report) has been assigned an average rating of "Hold" from the ten research firms that are currently covering the company, MarketBeat reports. Two investmen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
05:07pm, Thursday, 05'th Mar 2026
NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to c
Earnings Preview: Gossamer Bio (GOSS) Q4 Earnings Expected to Decline
11:01am, Thursday, 05'th Mar 2026
Gossamer Bio (GOSS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP
06:50pm, Wednesday, 04'th Mar 2026
Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More Likely NEW YORK, March 4, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDA
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Gossamer Bio, Inc. (GOSS)
03:43pm, Tuesday, 03'rd Mar 2026
New York, New York--(Newsfile Corp. - March 3, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerni
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
04:07pm, Sunday, 01'st Mar 2026
LOS ANGELES--(BUSINESS WIRE)---- $GOSS--GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm.
